Clinical Trial Update: Lokelma for RAAS Maximisation in CKD & Heart Failure. [Phase 3]

View source ↗

Summary

Phase 3 trial update for Lokelma aimed at maximizing RAAS inhibition in CKD and heart failure with reduced ejection fraction; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: St George's, University of London | Conditions: Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: COMPLETED